Cardiac amyloidosis (CA) is a complex disease considered to be the most common
underdiagnosed form of restrictive cardiomyopathy. Accumulation of misfolded proteins …

Background: Amyloidosis includes a diverse group of rare diseases characterized by the
misfolding of native or mutant proteins, leading to extracellular accumulation in various …

Light chain (AL) amyloidosis is a rare plasma cell dyscrasia. An estimated 12,000 people
live with the disease in the United States. AL amyloidosis occurs from the misfolding of …

Light-chain (AL) amyloidosis is a systemic syndrome characterized by progressive organ
dysfunction leading to organ failure and death. The heart is the most commonly involved …

Background: Limited data exists on the prognostic impact of valvular heart disease in
cardiac amyloidosis (CA). We therefore sought to define the prevalence of valvular disease …

Amyloidosis is a rare protein misfolding disease caused by the accumulation of amyloid
fibrils in various tissues and organs. There are different subtypes of amyloidosis, with light …

Nanoparticles hold a great potential for therapeutic targeting due to their ability to improve
the stability of encapsulated cargo and promote the transport of cargo across membranes to …

Bortezomib, a proteasome inhibitor (PI), has shown efficacy in the treatment of newly
diagnosed and relapsed light chain (AL) amyloidosis, and is often used in combination with …

Las amiloidosis sistémicas constituyen un grupo de enfermedades con diversas etiologías,
caracterizadas por la síntesis de proteínas con plegado defectuoso, capaces de agregarse y …

Amyloidosis refers to a group of disorders that stems from the ability of certain proteins to
adopt an unstable tertiary structure by misfolding and aggregating. The misfolding and …